ClinicalTrials.gg

Program

olsutamig

Also written as “REGN15505+REGN4336” and “REGN4336”.

Its studies are mostly in Carcinoma, Renal Cell · Prostatic Neoplasms, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Oct 25, 20212 company-led studies, 2 open or runningNext primary completion: Mar 28, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals22 open or runningphase 2since Oct 25, 2021Oct 25, 2021Mar 28, 2030phase 2 · NCT05125016

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2021First study: phase 2 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT05125016 · 228 planned · United States
  2. May 11, 2026Phase 2 study in Carcinoma, Renal CellNCT07594106 · 265 planned · United States

Ahead

  1. Mar 28, 2030Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT05125016
  2. Oct 27, 2030Primary completion: phase 2 study in Carcinoma, Renal CellNCT07594106

TargetBeta

CD3E →FOLH1 →read by rule
“A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514ruleGlaxoSmithKlinephase 21
Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014rulejanux-therapeuticsphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07594106Carcinoma, Renal Cell · United States2RecruitingOct 27, 2030265
NCT05125016Metastatic Castration-resistant Prostate Cancer · United States2RecruitingMar 28, 2030228

How it is read

Names in the registry

  • “REGN15505+REGN4336”, 1 entry
  • “REGN4336”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.